Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 3, 2008, Pages 499-506

  Parkkonen, Jouni ^a   Hasala, Hannele ^a   Moilanen, Eeva ^a   Giembycz, Mark A ^b   Kankaanranta, Hannu ^a,c,d  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF CALGARY   (Canada)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

Apoptosis; CAMP; CGMP; Eosinophils; GM CSF; Neutrophils; PDE inhibitors; Salbutamol

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA2 ADRENOCEPTOR AGONIST; BUDESONIDE; CILOSTAZOL; CORTICOSTEROID; CYTOKINE; LIPOCORTIN 5; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; ROLIPRAM; SALBUTAMOL; ZAPRINAST;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; EOSINOPHIL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NEUTROPHIL; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANNEXIN A5; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BUDESONIDE; CELL SURVIVAL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DNA FRAGMENTATION; EOSINOPHILS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; NEUTROPHILS; PHOSPHODIESTERASE INHIBITORS; PURINONES; ROLIPRAM; TETRAZOLES;

EID: 43049156207     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2007.11.003     Document Type: Article

References (39)

1. Watt A.P., Schock B.C., and Ennis M. Neutrophils and eosinophils: clinical implications of their appearance, presence and disappearance in asthma and COPD. Curr Drug Targets Inflamm Allergy 4 (2005) 415-423
2. Kankaanranta H., Moilanen E., and Zhang X. Pharmacological regulation of human eosinophil apoptosis. Curr Drug Targets Inflamm Allergy 4 (2005) 433-445
3. Giembycz M.A., and Lindsay M.A. Pharmacology of the eosinophil. Pharmacol Rev 51 (1999) 213-340
4. Ward C., Dransfield I., Chilvers E.R., Haslett C., and Rossi A.G. Pharmacological manipulation of granulocyte apoptosis: potential therapeutic targets. Trends Pharmacol Sci 20 (1999) 503-509
5. Haslett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 160 (1999) S5-S11
6. Torphy T.J., and Page C. Phosphodiesterases: the journey towards therapeutics. Trends Pharmacol Sci 21 (2000) 157-159
7. Souness J.E., Aldous D., and Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47 (2000) 127-162
8. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157 (1998) 351-370
9. Giembycz M.A. Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 326-333
10. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 20-22
11. Kankaanranta H., Lindsay M.A., Giembycz M.A., Zhang X., Moilanen E., and Barnes P.J. Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol 106 (2000) 77-83
12. Chang H.S., Jeon K.W., Kim Y.H., Chung I.Y., and Park C.S. Role of cAMP-dependent pathway in eosinophil apoptosis and survival. Cell Immunol 203 (2000) 29-38
13. Peacock C.D., Misso N.L., Watkins D.N., and Thompson P.J. PGE 2 and dibutyryl cyclic adenosine monophosphate prolong eosinophil survival in vitro. J Allergy Clin Immunol 104 (1999) 153-162
14. Yasui K., Hu B., Nakazawa T., Agematsu K., and Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 100 (1997) 1677-1684
15. Parvathenani L.K., Buescher E.S., Chacon-Cruz E., and Beebe S.J. Type I cAMP-dependent protein kinase delays apoptosis in human neutrophils at a site upstream of caspase-3. J Biol Chem 273 (1998) 6736-6743
16. Martin M.C., Dransfield I., Haslett C., and Rossi A.G. Cyclic AMP regulation of neutrophil apoptosis occurs via a novel protein kinase A-independent signaling pathway. J Biol Chem 276 (2001) 45041-45050
17. Krakstad C., Christensen A.E., and Doskeland S.O. cAMP protects neutrophils against TNF-alpha-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). J Leukoc Biol 76 (2004) 641-647
18. Kankaanranta H., Ilmarinen P., Zhang X., Nissinen E., and Moilanen E. Antieosinophilic activity of orazipone. Mol Pharmacol 69 (2006) 1861-1870
19. Kankaanranta H., De Souza P.M., Barnes P.J., Salmon M., Giembycz M.A., and Lindsay M.A. SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther 290 (1999) 621-628
20. Kankaanranta H., De Souza P.M., Giembycz M.A., and Lindsay M.A. Human eosinophil isolation and the measurement of apoptosis. In: Chung K.F., and Adcock I.M. (Eds). Methods in molecular medicine: asthma vol. 44 (2000), Humana press, London 99-110
21. Zhang X., Moilanen E., Adcock I.M., Lindsay M.A., and Kankaanranta H. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci 71 (2002) 1523-1534
22. Jonkman J.H., Freie H.M., van der Boon W.J., and Grasmeijer G. Single dose absorption profiles and bioavailability of two different salbutamol tablets. Arzneimittel-Forschung 36 (1986) 1133-1135
23. Powell M.L., Chung M., Weisberger M., Gural R., Radwanski E., Symchowicz S., et al. Multiple-dose albuterol kinetics. J Clin Pharmacol 26 (1986) 643-646
24. Hochhaus G., and Mollmann H. Pharmacokinetic/pharmacodynamic characteristics of the β-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol 30 (1992) 342-362
25. Kung T.T., Crawley Y., Luo B., Young S., Kreutner W., and Chapman R.W. Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines. Br J Pharmacol 130 (2000) 457-463
26. Santing R.E., de Boer J., Rohof A., van der Zee N.M., and Zaagsma J. Bronchodilatory and anti-inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma. Eur J Pharmacol 429 (2001) 335-344
27. Kanehiro A., Ikemura T., Makela M.J., Lahn M., Joetham A., Dakhama A., et al. Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 163 (2001) 173-184
28. Tenor H., Hatzelmann A., Church M.K., Schudt C., and Shute J.K. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 118 (1996) 1727-1735
29. Silva P.M., Alves A.C., Serra M.F., Pires A.L., Silva J.P., Barreto E.O., et al. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme. Br J Pharmacol 134 (2001) 283-294
30. Liu J., Munoz N.M., Meliton A.Y., Zhu X., Lambertino A.T., Xu C., et al. Beta2-integrin adhesion caused by eotaxin but not IL-5 is blocked by PDE-4 inhibition and beta2-adrenoceptor activation in human eosinophils. Pulm Pharmacol Ther 17 (2004) 73-79
31. Zhang X., Moilanen E., and Kankaanranta H. Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol 406 (2000) 325-332
32. Zhang X., Moilanen E., and Kankaanranta H. Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol 431 (2001) 365-371
33. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 (2005) 167-175
34. Zhang X., Moilanen E., Lahti A., Hämäläinen M., Giembycz M.A., Barnes P.J., et al. Regulation of eosinophil apoptosis by nitric oxide: role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5. J Allergy Clin Immunol 112 (2003) 93-101
35. Barnes P.J. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 167 (2003) 813-818
36. Yasui K., Agematsu K., Shinozaki K., Hokibara S., Nagumo H., Nakazawa T., et al. Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J Leukoc Biol 67 (2000) 529-535
37. Brunetti M., Mascetra N., Manarini S., Martelli N., Cerletti C., Musiani P., et al. Inhibition of cGMP-dependent protein kinases potently decreases neutrophil spontaneous apoptosis. Biochem Biophys Res Commun 297 (2002) 498-501
38. Momose T., Okubo Y., Horie S., Suzuki J., Isobe M., and Sekiguchi M. Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression. Int Arch Allergy Immunol 117 (1998) 138-145
39. Hallsworth M.P., Giembycz M.A., Barnes P.J., and Lee T.H. Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF. Br J Pharmacol 117 (1996) 79-86